Non-redundant activity of GSK-3α and GSK-3β in T cell-mediated tumor rejection
Open Access
Abstract
No abstract availableKeywords
Funding Information
- University of Leeds
- Wellcome Trust (204825/Z/16/Z)
- Cancer Research UK (C11071/A20105)
This publication has 34 references indexed in Scilit:
- T-bet in diseaseNature Immunology, 2011
- Glycogen Synthase Kinase-3 Is an Early Determinant in the Differentiation of Pathogenic Th17 CellsThe Journal of Immunology, 2011
- GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSFrontiers in Molecular Neuroscience, 2011
- Glycogen synthase kinase 3: more than a namesakeBritish Journal of Pharmacology, 2009
- New insights into the regulation and function of serine/threonine kinases in T lymphocytesImmunological Reviews, 2009
- TcR and TcR-CD28 Engagement of Protein Kinase B (PKB/AKT) and Glycogen Synthase Kinase-3 (GSK-3) Operates Independently of Guanine Nucleotide Exchange Factor VAV-1Journal of Biological Chemistry, 2006
- Toll-like receptor–mediated cytokine production is differentially regulated by glycogen synthase kinase 3Nature Immunology, 2005
- GSK3 takes centre stage more than 20 years after its discoveryBiochemical Journal, 2001
- Glycogen Synthase Kinase-3 Inhibits the DNA Binding Activity of NFATcJournal of Biological Chemistry, 2001
- Multisite phosphorylation of glycogen synthase from rabbit skeletal muscleFEBS Letters, 1982